Best Life Sciences Companies in Heidelberg, Germany
The 46 best Life Sciences companies in Heidelberg, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Novaliq.
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in Heidelberg
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Novaliq Developer of reformulation of drug for ocular therapeutics | $115M | 94 mo ago | Series C | Christian Roesky Chief Executive Officer / Managing Director | 2007 | WordPressMySQLPHP+7 | 670 patents Ophthalmic drug formulations and delivery systems for dry eye, uveitis, and neovascular diseases | — |
| 2 | Affimed Therapeutics Developer of antibody therapeutic solutions for cancer treatment | $90M | 139 mo ago | Public | Adi Hoess CEO | 2000 | WordPressApple iCloud MailMicrosoft 365+15 | 56 patents Multivalent antibody fragments for CD16 and EGFRvIII targeting in immunotherapy | — |
| 3 | Cellzome Small-molecule kinase targeted drugs to treat inflammatory diseases | $78M | 212 mo ago | Acquired | — | 2000 | — | 201 patents Enzyme‑focused small‑molecule drug discovery and target‑validation platforms | — |
| 4 | Apogenix Developer of novel protein therapeutics for the treatment of cancer and inflammatory diseases | $72M | 56 mo ago | Series B | — | 2005 | — | 369 patents Patents concentrated in chemistry & materials | — |
| 5 | Molecular Health Genomic software solutions for healthcare providers | $27M | 129 mo ago | Late Stage | Friedrich Bohlen Founder & CEO | 2004 | WordPress Site EditorWordPressApple iCloud Mail+20 | 59 patents Patents concentrated in computing, sensing & instrumentation | — |
| 6 | Luxendo Manufacturer of light-sheet fluorescence microscopes for 3D bioimaging | $8M | 115 mo ago | Acquired | — | 2015 | — | — | 1 award |
| 7 | Epignostix Developer of DNA methylation-based therapeutics for tumor classification | $5M | 25 mo ago | Seed | Daniel Schrimpf Co-Founder | 2022 | — | — | — |
| 8 | VERAXA Developer of antibody therapeutics for cancer treatment | $3M | 85 mo ago | Series B | Edward A. Lemke Co-Founder | 2017 | WebflowMicrosoft Advertisingcore-js+10 | — | 1 partnership |
| 9 | Precisis Portfolio of devices and tools for neurological surgery | $3M | 50 mo ago | Funding Raised | — | 2002 | WordPress Site EditorWordPressMySQL+14 | 82 patents Implantable neurostimulation electrodes and lead connectors for seizure and neural therapy | — |
| 10 | Sciomics Enabling Precision Medicine through Advanced Protein Biomarkers | $719K | 104 mo ago | Funding Raised | Christoph Schroeder Founder & CEO | 2013 | JoomlaPHPBootstrap+16 | 8 patents Predictive molecular diagnostics for COVID-19 severity and acute kidney injury risk assessment | — |
| 11 | PEPperPRINT Provides the peptide microarray platform | $676K | 72 mo ago | Seed | — | 2010 | TYPO3 CMSPleskPHP+22 | 12 patents High‑density peptide microarray production and Zika NS2b antigen diagnostic assay development. | 1 launch |
| 12 | Biobyte solutions Provider of customized bioinformatics tools and consulting services | $606K | 91 mo ago | Funding Raised | Ivica Letunic CEO | 2005 | UbuntuBootstrapApache HTTP Server+7 | — | — |
Top 12 Life Sciences companies in Heidelberg
#1
Seed · Heidelberg, Baden-wurttemberg · founded 2022$4.6Mraised▾
Developer of DNA methylation-based therapeutics for tumor classification. It revolutionize tumor classification by harnessing the power of methylation-based models to improve diagnosis, prognosis, and treatment decisions.
- Jul 2024Seed$4.6M
#2
Series B · Heidelberg, Baden-wurttemberg · founded 2005 · 57 employees$72.3Mraised▾
Developer of novel protein therapeutics for the treatment of cancer and inflammatory diseases. The compound´s mechanism of action is either based on the targeted modulation of the programmed cell death or on the inhibition of tumour cell growth. The lead product is APG101 (fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc domain of an IgG antibody) is being developed for the treatment of Glioblastoma multiforme and myelodysplastic syndrome.
- Dec 2021Series B$29.4M
- Apr 2008Series B$42.9M
#3
Series C · Heidelberg, Baden-wurttemberg · founded 2007 · 30 employees$115Mraised▾
Novaliq is developing reformulated drug products based on semi-fluorinated alkanesfor ocuar therapeutics. Its proprietary platform uses semi-fluorinated alkanes as a delivery alternative to water, and drug carriers being perfluorohexyloctane and perfluorobutylpentane. The company has an approved OTC product called NovaTears to cure a mild dry eye. In addition, the company has another compound called CyclASol for a severe dry eye which in phase 3 trials. Its a non-aqueous and preservative-free formulation containing cyclosporine.
- Oct 2018Series C$53M
- Jan 2016Grant (prize money)$162.1K
- Apr 2013Series B$18.1M
- May 2012Series A$5.1M
#4
Public · Heidelberg, Baden-wurttemberg · founded 2000 · 197 employees$89.7Mraised▾
Developer of antibody therapeutic solutions for cancer treatment. It is a biopharmaceutical company, engages in the discovery and development of recombinant antibody therapeutics for the treatment of cancer and other diseases. It offers a tetravalent antibody that is targeting tumor cells. The company also provides programs for the treatment of Non-Hodgkin's Lymphoma, Hodgkin's diseases, thrombosis and autoimmune, leukemia, myeloma, solid tumors, metastasis, non-cancer indications, allergy, and asthma diseases.
- Jan 2015Grant (prize money)$3M
- Oct 2012Series D$20.1M
- Apr 2010Series C$26.4M
- Feb 2008Series B$7.4M
#5
Funding Raised · Heidelberg, Baden-wurttemberg · founded 2002 · 14 employees$2.8Mraised▾
Precisis develops technologies and devices to treat various neurological conditions. The company's products include - Praezis Plus, a stereotactic 3D design software designed for the optimization of neurological surgical procedures; CobraLeaf MLC system that provides the ability to conform Cobalt-60 radiotherapy to the exact tumor shape without the cumbersome use of lead blocks. The company also provides EASEE, a minimally invasive brain stimulation system placed directly under the scalp for the treatment of epilepsy. In addition, the company offers surgical tools and radiation protection systems for neurosurgical brachytherapy, implantation hardware, and collimators. It provides solutions for precision interventions in neurosurgery, radiotherapy, and stereotaxy; and Parkinson's and tumors.
- 2022Grant (prize money)$2.8M
#6
Acquired · Heidelberg, Baden-wurttemberg · founded 2000 · 90 employees$78.1Mraised▾
Cellzome is a drug discovery company focussed on developing a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline small-molecule therapeutics is based on Kinobeads, a proprietary technology for screening and profiling kinases in relevant cells and tissues. Its small molecules target inflammatory mediators such as PI3Kg and Zap-70, Jak3 and mTOR and have a potential to be oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and asthma. It was acquired by GSK for $99M in May 2012.
- Dec 2008Grant (prize money)$4.9M
- Mar 2003Series C$47.1M
- Mar 2001Series B$31M
#7
Late Stage · Heidelberg, Baden-wurttemberg · founded 2004 · 121 employees$26.9Mraised▾
Genomic software solutions for healthcare providers. Its proprietary Dataome platform is a SaaS product and is capable of converting both structured and unstructured NGS data into clinically actionable results. The Dataome Knowledgebase contains information for 97k drugs, 54M drug names, 4.6M drug interactions, 85k genomic variants, and 109k clinical trials. Currently, Molecular Health has three products based on its technology. MH Guide Labs converts genetic variant data into a comprehensive tumor profile to enable labs with NGS capabilities. MH Guide Hospitals is an enterprise solution that uses sequencing data to evaluate drug efficacy, drug-drug interactions, and drug-patient compatibility for tailored cancer therapies. MH Effect is a specialized product that predicts drug-drug interactions and drug-induced adverse effects by using patient genomic data.
- Nov 2015PE$26.9M
#8
Acquired · Heidelberg, Baden-wurttemberg · founded 2015 · 20 employees$8.4Mraised▾
Manufacturer of light-sheet fluorescence microscopes for 3D bioimaging. These microscopes enable fast, high-resolution imaging of live or cleared tissue samples, avoiding phototoxicity. The company offers various models suited for diverse applications, including imaging of cleared samples, live samples, organoids, and embryos. Supporting software integrates microscopy control, image viewing, and post-processing. Additional modules enhance functionality, offering photomanipulation, environmental control, and improved image quality. The company also provides resources such as FAQs, educational materials, and webinars to support researchers.
- Jan 2017Series A$8.4M
- 2015Seed—
#9
Series B · Heidelberg, Baden-wurttemberg · founded 2017 · 36 employees$3.4Mraised▾
Developer of antibody therapeutics for cancer treatment. The company is focusing on ADC engineering and functional antibody screening for the treatment of oncological conditions. The company’s droplet-based microfluidic screening technology and its innovative antibody and protein conjugation technology allow for a rapid generation of antibodies against the most complex target molecules.
- Jun 2019Series B$3.4M
#10
Seed · Heidelberg, Baden-wurttemberg · founded 2010 · 29 employees$676Kraised▾
PEPperPRINT provides platform for high-density peptide microarrays with virtually unlimited content flexibility covering any peptide or protein sequence. PEPperCHIP® Custom Peptide Microarrays can be tailored to specific scientific needs from single antigens translated into overlapping peptides for multiple epitope mappings per chip to whole virus proteomes for epitope and antigen discovery in e.g. patient and control sera. Applications are Antigen/Biomarker Discovery, Antibody epitope mapping and substitution scan, Serum antibody profiling before and after drug administration, Determination of humoral immune response to different adjuvants, Vaccine and peptide drug development, Protein target binder identification and optimization, etc.
- Aug 2020Grant (prize money)$448.7K
- Jan 2020Grant (prize money)$423.4K
- Mar 2010Seed$676K
#11
Funding Raised · Heidelberg, Baden-wurttemberg · founded 2005$605.5Kraised▾
Biobyte Solutions is a provider of customized bioinformatics software tools and services. It provides custom data management and visualization solutions, used in various large-scale collaborative projects. They also provide bioinformatics consultation, biological database maintenance, and metagenomics data analysis. The company participated in EU funded research consortia such as MODHEP central data repository development, hosting and management.
- Jan 2019Grant (prize money)$332.4K
- Mar 2016Grant (prize money)$273.2K
#12
Funding Raised · Heidelberg, Baden-wurttemberg · founded 2013$718.5Kraised▾
Sciomics offers highly-parallel protein analyses with antibody microarrays for pathway profiling, biomarker screening and verification.
- Dec 2017Grant (prize money)$718.5K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Heidelberg is moving
A read on the academic research around Biotechnology in Heidelberg — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 90 papers.
- Heidelberg University85
- University Hospital Heidelberg29
- Hopp Children\'s Cancer Center Heidelberg7
- Heidelberg Institute for Theoretical Studies4
- Heidelberg Engineering2
- Biodistribution5
- Cancer research4
- DNA methylation4
- Cancer4
- Microvesicles4
- Mesenchymal stem cell4
- Gene expression3
- Glioma3
- Cell2
- Epitope2
- Cell culture2
- Mutation2
- Gene expression2
- Efflux2
- Rifampicin2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.